GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Shiller PE Ratio

TCRT (Alaunos Therapeutics) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alaunos Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Alaunos Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Shiller PE Ratio Chart

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alaunos Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alaunos Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Alaunos Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Shiller PE Ratio falls into.



Alaunos Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alaunos Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Alaunos Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.7/133.0289*133.0289
=-0.700

Current CPI (Sep. 2024) = 133.0289.

Alaunos Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -13.500 99.070 -18.128
201503 -103.500 99.621 -138.209
201506 -16.500 100.684 -21.801
201509 -21.000 100.392 -27.827
201512 -10.500 99.792 -13.997
201603 -13.500 100.470 -17.875
201606 -151.500 101.688 -198.193
201609 -16.500 101.861 -21.549
201612 -16.500 101.863 -21.548
201703 -22.500 102.862 -29.099
201706 -19.500 103.349 -25.100
201709 -19.500 104.136 -24.910
201712 -19.500 104.011 -24.940
201803 -22.500 105.290 -28.428
201806 -18.000 106.317 -22.523
201809 -19.500 106.507 -24.356
201812 193.500 105.998 242.845
201903 -12.000 107.251 -14.884
201906 -13.500 108.070 -16.618
201909 -64.500 108.329 -79.206
201912 -13.500 108.420 -16.564
202003 -13.500 108.902 -16.491
202006 -13.500 108.767 -16.511
202009 -15.000 109.815 -18.171
202012 -16.500 109.897 -19.973
202103 -15.000 111.754 -17.856
202106 -16.500 114.631 -19.148
202109 -16.500 115.734 -18.966
202112 -7.500 117.630 -8.482
202203 -7.500 121.301 -8.225
202206 -7.500 125.017 -7.981
202209 -6.000 125.227 -6.374
202212 -6.000 125.222 -6.374
202303 -6.300 127.348 -6.581
202306 -5.490 128.729 -5.673
202309 -5.300 129.860 -5.429
202312 -4.898 129.419 -5.035
202403 -1.100 131.776 -1.110
202406 -0.710 132.554 -0.713
202409 -0.700 133.029 -0.700

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alaunos Therapeutics  (NAS:TCRT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alaunos Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129